Gilead forecasts FY26 Yeztugo revenue at about $1 billion

• Gilead guided for FY26 HIV revenue growth of 9%-10% year over year, led by Biktarvy, Yeztugo, Descovy.
• FY26 Yeztugo revenue expected near USD 1 billion; Q2 sales reached USD 232 million, up 40% quarter over quarter.
• Cell therapy revenue forecast to fall by a mid-teens percentage in FY26; Q2 sales were USD 417 million, down 14% year over year.
• Veklury revenue outlook set at about USD 300 million for FY26; Q2 sales were USD 23 million, down 81% year over year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.